Immunomedics Financials

Immunomedics Stock Summary

Immunomedics competes with Beyond, Cedar Realty, MYT Netherlands, LB Foster, and Integrated Media. Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc. Immunomedics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 366 people.

Immunomedics Key Financial Ratios

Generally speaking, Immunomedics' financial ratios allow both analysts and investors to convert raw data from Immunomedics' financial statements into concise, actionable information that can be used to evaluate the performance of Immunomedics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Immunomedics reports annually and quarterly.

Immunomedics Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Immunomedics's current stock value. Our valuation model uses many indicators to compare Immunomedics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunomedics competition to find correlations between indicators driving Immunomedics's intrinsic value. More Info.Immunomedics is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunomedics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunomedics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunomedics' earnings, one of the primary drivers of an investment's value.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

If you are still planning to invest in Immunomedics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immunomedics' history and understand the potential risks before investing.